Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.

Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.

Abstract: The present invention provides therapeutic compositions and methods for treating disease conditions in humans associated with an antigen specific immune response by the human to an antigen such as a protein antigen (i.e. allergy and autoimmune diseases). Therapeutic compositions of the invention are reproducible preparations which are suitable for human therapy. Compositions of the invention comprise at least one isolated peptide having a defined sequence of amino acid residues and the composition is capable of down regulating an antigen specific immune response to an offending antigen in a population of humans subject to the antigen specific immune response. Compositions and methods of the invention may be used to treat sensitivity to protein allergens in humans and may also be used to treat autoimmune disease such as rheumatoid arthritis, diabetes, myasthenia gravis, Grave's disease, Good Pasture's syndrome, thyroiditis and multiple sclerosis.

Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.

Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.

Abstract: Methods of affecting secondary metabolite production and secondary metabolite production profiles in plant cell and tissue cultures with DNA methylation inhibitors and elicitor systems.

Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.

Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.

Abstract: The use of phenylglyoxylic acids and derivatives thereof in the treatment of ischemic heart disease and the hyperglycemia of diabetes.

Abstract: The use of phenylglyoxylic acids and derivatives thereof in the treatment of ischemic heart disease and the hyperglycemia of diabetes.

Abstract: L- and DL- Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.

Abstract: L- and DL- Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.

Abstract: L- and DL- Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.

Abstract: L- and DL-Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.

Abstract: L- and DL-Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.

Abstract: L- and DL- Phenylglycines of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or methyl and R.sup.1 is NH.sub.2, OH or completes a carboxylic ester group, useful in treating certain cardiovascular diseases, diabetes and obesity.